Research graph
References from National-level estimation of long-term economic burden for lung cancer patients in China. Local targets link to admitted publications; unresolved targets remain external evidence.
Analysis of the prevalence of malignant tumors in China in 2022
2024 · External reference
Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050
10.1001/jamaoncol.2022.7826 · 2023 · External reference
Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017–2030
10.21147/j.issn.1000-9604.2021.01.09 · 2021 · External reference
Health economic evaluation and analysis of prognosis, economic burden and screening strategies for lung cancer patients in the early diagnosis and treatment screening project of lung cancer in some areas of China
2022 · External reference
Analysis of hospitalization expenses and influencing factors of lung cancer patients from 2015 to 2020
2021 · External reference
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
10.1080/13696998.2023.2272536 · 2023 · External reference
Analysis on the incidence and economic burden of patients with lung cancer
10.3779/j.issn.1009-3419.2022.101.09 · 2022 · External reference
Chinese expert consensus on diagnosis and treatment of pulmonary nodules (2024 Edition)
2024 · External reference
The global burden of lung cancer: current status and future trends
10.1038/s41571-023-00798-3 · 2023 · External reference
Unresolved reference
2017 · External reference
The national economic burden of rare disease in the United States in 2019
10.1186/s13023-022-02299-5 · 2022 · External reference
Unresolved reference
2018 · External reference
Analysis of the follow-up survival status of 11,333 lung cancer patients in the Third Affiliated Hospital of Xinjiang Medical University
2023 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2017 · External reference
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
10.1186/s13561-021-00322-2 · 2021 · External reference
Analysis of the direct non-medical economic burden and influencing factors of patients with advanced non-squamous non-small cell lung cancer
2022 · External reference
Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?
10.3389/fpubh.2023.1090623 · 2023 · External reference
Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China
10.1007/s00432-022-04258-w · 2023 · External reference
How do treatment preferences of patients with cancer compare with those of oncologists and family members? Evidence from a discrete choice experiment in China
10.1016/j.jval.2022.05.003 · 2022 · External reference
Socioeconomic burden of cancer in Korea from 2011 to 2015
10.4143/crt.2019.398 · 2020 · External reference
Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage
10.1186/s12885-019-5428-4 · 2019 · External reference
The impact of bundled payment on the economic burden and satisfaction of patients in Close-Knit County Medical Community in China
10.3389/fpubh.2025.1530176 · 2025 · External reference
